EMEA-001474-PIP01-13-M01 - paediatric investigation plan
Anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475) (pembrolizumab)
PIPHuman
Merck Sharp & Dohme (Europe), Inc
Tel. +33 1804 64738
E-mail: pip.information@merck.com
P/0043/2018: EMA decision of 16 February 2018 on the acceptance of a modification of an agreed paediatric investigation plan for pembrolizumab (Keytruda), (EMEA-001474-PIP01-13-M01)